Jul
09
2025
Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia
Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson …